Acromegaly - Pipeline Review, H1 2018

  • ID: 4491155
  • Drug Pipelines
  • 80 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aegis Therapeutics LLC
  • Aquestive Therapeutics
  • DexTech Medical AB
  • Italfarmaco SpA
  • Midatech Pharma Plc
  • Peptron Inc
  • MORE
Acromegaly - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H1 2018, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 5, 1, 5 and 3 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aegis Therapeutics LLC
  • Aquestive Therapeutics
  • DexTech Medical AB
  • Italfarmaco SpA
  • Midatech Pharma Plc
  • Peptron Inc
  • MORE
Introduction

Report Coverage

Acromegaly - Overview

Acromegaly - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly - Companies Involved in Therapeutics Development

Aegis Therapeutics LLC

Amryt Pharma plc

Antisense Therapeutics Ltd

Aquestive Therapeutics

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Ionis Pharmaceuticals Inc

Italfarmaco SpA

leon-nanodrugs GmbH

Midatech Pharma Plc

Novartis AG

Peptron Inc

Silence Therapeutics Plc

Strongbridge Biopharma plc

Sun Pharmaceutical Industries Ltd

Acromegaly - Drug Profiles

Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRN-00808 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leon-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate long acting - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly - Dormant Projects

Acromegaly - Discontinued Products

Acromegaly - Product Development Milestones

Featured News & Press Releases

Feb 28, 2018: ATL1103/atesidorsen Early Access Program - Update

Jan 30, 2018: FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals DP1038 for the Treatment of Acromegaly

Jan 09, 2018: Midatech receives confirmation that its Q-Octreotide (MTD201) first in-human EU study is approved

Jan 08, 2018: Chiasma Reports on Significant Progress Made During 2

Dec 22, 2017: Antisense Therapeutics Executes Agreement to Implement ATL1103 / atesidorsen Early Access Program for Patients with Acromegaly

Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly

Oct 19, 2017: Clinical Data from Phase 1 PK/PD Study of Octreotide for Intranasal Delivery to be Presented at North American Neuroendocrine Tumor Society Symposium

Sep 27, 2017: Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly

Sep 04, 2017: Midatech Submits MTD201 CTA Filing For First-in Human Study in Carcinoid Cancer and Acromegaly

Aug 10, 2017: Chiasma Reaches Agreement with FDA under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly

Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00

May 04, 2017: Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

Feb 23, 2017: ATL1103 Update - proposed International Nonproprietary Name for ATL1

Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Acromegaly, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Acromegaly - Pipeline by Aegis Therapeutics LLC, H1 2018

Acromegaly - Pipeline by Amryt Pharma plc, H1 2018

Acromegaly - Pipeline by Antisense Therapeutics Ltd, H1 2018

Acromegaly - Pipeline by Aquestive Therapeutics, H1 2018

Acromegaly - Pipeline by Chiasma Inc, H1 2018

Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H1 2018

Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018

Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H1 2018

Acromegaly - Pipeline by DexTech Medical AB, H1 2018

Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Acromegaly - Pipeline by Italfarmaco SpA, H1 2018

Acromegaly - Pipeline by leon-nanodrugs GmbH, H1 2018

Acromegaly - Pipeline by Midatech Pharma Plc, H1 2018

Acromegaly - Pipeline by Novartis AG, H1 2018

Acromegaly - Pipeline by Peptron Inc, H1 2018

Acromegaly - Pipeline by Silence Therapeutics Plc, H1 2018

Acromegaly - Pipeline by Strongbridge Biopharma plc, H1 2018

Acromegaly - Pipeline by Sun Pharmaceutical Industries Ltd, H1 2018

Acromegaly - Dormant Projects, H1 2018

Acromegaly - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Acromegaly, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aegis Therapeutics LLC
  • Amryt Pharma plc
  • Antisense Therapeutics Ltd
  • Aquestive Therapeutics
  • Chiasma Inc
  • Crinetics Pharmaceuticals Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dauntless Pharmaceuticals Inc
  • DexTech Medical AB
  • Ionis Pharmaceuticals Inc
  • Italfarmaco SpA
  • leon-nanodrugs GmbH
  • Midatech Pharma Plc
  • Novartis AG
  • Peptron Inc
  • Silence Therapeutics Plc
  • Strongbridge Biopharma plc
  • Sun Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll